I've done enough inspection readiness work at CGT sites to know exactly what's about to happen.
The FDA released new guidance on January 11th softening CMC requirements for cell and gene therapy manufacturers. Three specific changes: manufacturers no longer need to meet full cGMP requirements under 21 CFR Part 211 before Phase 2 or 3 trials, the fixed requirement for three Process Performance Qualification lots before commercial production is gone, and post-approval manufacturing specifications can now be revised based on real-world experience.
The industry celebrated. Innovation accelerated. Barriers removed.
And somewhere right now, a VP of Manufacturing at an early-stage CGT company is forwarding that press release to their head of quality with a note that says "see, we don't need to worry about this yet."
That's the problem.
Here's what the FDA actually said. They've been applying these flexibilities case-by-case for years. What changed on January 11th is that they decided to broadcast it broadly so every sponsor understands what's available, regardless of which review team they're working with. Commissioner Makary called it "common-sense reforms." CBER Director Vinay Prasad framed it as removing barriers for sponsors developing therapies for rare diseases with genuine unmet need.
None of that is wrong. The flexibility is real. The intent is legitimate.
But here's what I've watched happen at site after site when regulatory pressure decreases: quality infrastructure gets deprioritized. Not dramatically. Not all at once. It happens slowly, the same way it always happens. Training gets underfunded because you don't technically need a fully built program yet. SOPs get written in draft form and nobody pushes to finalize them because there's no immediate audit forcing the issue. Process understanding stays in the heads of your three most senior operators because you haven't built the systems to capture and transfer it.
And then you hit BLA.
The Flexibility Demands More, Not Less
Here's the kicker. The FDA's flexibility actually demands more process understanding, not less. Dropping the three-lot PPQ requirement doesn't mean you need less validation. It means the strategy you do have needs to be scientifically justified based on your specific process, your specific product, and your specific risk profile. That requires a team that deeply understands what they're manufacturing and why each step matters. That understanding comes from structured training and documented competency development. You can't build it in the six months before your pre-BLA inspection.
I've seen this play out more times than I can count. A company breezes through clinical manufacturing on a skeleton crew of brilliant scientists who know the process intuitively. They hit commercial scale, headcount triples overnight, and suddenly you're trying to transfer tacit knowledge from three people to thirty while an FDA investigator is scheduled to walk through your door in eight months.
The training program that should have been built during Phase 1? Doesn't exist. The SOPs that should have been tightened during Phase 2? Still in draft. The competency framework that should have been validated during Phase 3? Nobody got around to it because the science was working and there was no immediate consequence for deferring.
I guarantee if you walked into ten CGT sites right now, at least seven of them are in some version of this situation. Not because the teams are incompetent. Because the incentives during clinical development consistently point away from building infrastructure that doesn't feel immediately necessary.
The Phase 2/3 cGMP Compliance Question
The flexibility around Phase 2/3 cGMP compliance is the one that concerns me most. There are legitimate reasons it exists. Small patient populations, time-critical manufacturing, resource constraints at early-stage companies. All real. But the companies that benefit from this flexibility are the ones that still treat cGMP as a standard to build toward, not a requirement they've been given permission to avoid.
Here's a fun exercise. Ask your Phase 2 manufacturing team how they'd handle a deviation that occurs during a commercial campaign. If the answer involves someone saying "well, we'd figure it out," you have a training infrastructure problem that no amount of regulatory flexibility is going to solve at BLA.
What the Companies That Get It Right Have in Common
The companies that actually get this right share a few things in common. They build training architecture during clinical development even when they don't have to. They document process understanding as it develops, not after the fact. They treat the loosened PPQ requirement as an opportunity to demonstrate more sophisticated process knowledge, not as permission to do less.
Flexibility compounds in your favor when you've done the foundational work. It punishes you when you haven't. The FDA is extending trust to the CGT field. The sites that honor that trust will move faster through development and cleaner through inspection. The sites that misread it as a permission slip to defer quality infrastructure will become the case studies the rest of us read at conferences.
I've spent the last decade helping companies on both sides of that line. The work required to land on the right side isn't complicated. It just needs to start earlier than most teams think.
Further reading: FDA, Flexible Requirements for Cell and Gene Therapies to Advance Innovation. January 11, 2026.